Phase I-II evaluation of weekly mitomycin-C (NSC-26980) for patients with metastatic GI and breast malignancies.
D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D013921:Thrombocytopenia / Q000139:chemically induced
D008937:Mitomycins